Drugs News and Research

RSS

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

Gap between Hispanic and white asthma sufferers widen in the use daily medications

The gap between the proportion of black and white Americans with asthma who took an inhaled or oral medicine daily to prevent attacks grew wider between 2003 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

12 May 2010

Daily dose of iron reduces breath-holding spells in children by 90%: Studies

An estimated one in 20 kids suffer from breath-holding spells, which come when they are upset, in pain or surprised. In some cases, the children twitch and jerk around involuntarily, as if they are having a seizure. Their faces sometimes turn blue or pale and they often faint.

12 May 2010

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).

12 May 2010

PharmedOut to host conference to explore influence of pharmaceutical industry on medical education

PharmedOut, an initiative aimed at increasing physician access to unbiased information about drugs, will host a conference to explore the issues of pharmaceutical industry funding on continuing medical education. The conference, "Prescription for Conflict: Should Industry Fund Continuing Medical Education?" will be held June 25, 2010 at Georgetown University.

12 May 2010

Studies: Trauma centers would be strained by patient load in terrorist attack

The Wall Street Journal reports that, according to experts and private studies, "[m]any urban hospitals lack sufficient medical staff, beds, equipment and 'surge' plans to provide optimal care for potentially hundreds or thousands of patients from a large bombing, emergency and trauma doctors say."

12 May 2010

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

The ZKB TECHNOPARK® Pioneer Award, which has been sponsored by the Zürcher Kantonalbank since 2000, was presented for the 20th time at TECHNOPARK® Zurich. The award is given for technological innovations which - thanks to pioneering entrepreneurial achievements - are about to be launched on the market. This year's award winner is Neurimmune Therapeutics AG, represented by Dr. Jan Grimm, Professor Christoph Hock, Professor Roger Nitsch and Dr. Michael Salzmann.

12 May 2010

Vetter signs preferred partnership agreement with Sentry BioPharma Services

Vetter, a leading provider of aseptic pre-filled drug-delivery systems, and Sentry BioPharma Services, a provider of supply chain management and clinical packaging services, today announced that they have signed a preferred partnership agreement.

12 May 2010

R.I. overhauls Medicaid payments for elderly, disabled; Medicaid delays reported in Kansas

Rhode Island received a waiver from the Bush administration to revamp its Medicaid program for the elderly and disabled, despite concerns from "community health activists [who] feared that it would push some of the neediest onto waiting lists or worse — throw some poor people off the Medicaid rolls altogether.

12 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences’ Luveniq NDA

Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye on June 28, 2010.

12 May 2010

Group worries about proposals to allow drug marketing on social media websites

The Center for Digital Democracy is concerned about proposals to allow pharmaceutical companies to market drugs on social media websites. Such a change is under examination by the Food and Drug Administration, the National Journal's Tech Daily Dose reports.

12 May 2010

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report.

12 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection has been granted regulatory approval for marketing and sale in Australia. Acetadote, an injectable drug used to treat acetaminophen (paracetamol) overdose, was approved by the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs and medical devices in Australia.

12 May 2010

Tianyin third-quarter revenue up 60%

Tianyin Pharmaceutical Co., Inc.,, a biopharmaceutical company that specializes in the modernized traditional Chinese medicine and branded generics today announced fiscal results for its third quarter ended March 31, 2010.

12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Bionovo reports net loss of $4.7M for first-quarter 2010

Bionovo, Inc. today announced first quarter highlights and financial results for the three months ended March 31, 2010.

12 May 2010

China Pharma first-quarter revenue up 16% to $15.1 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

11 May 2010

Minn. negotiators seek compromise to expand Medicaid while a nursing home tax and cuts to a screening program grab headlines in other states

The (Minneapolis) Star Tribune: Members of a legislative conference committee in Minnesota "agreed Sunday that expanding Medicaid should be part of the eventual compromise they will take to the House and Senate as early as Monday in a package of health and human service measures to cut the state's budget deficit. Gov. Tim Pawlenty has strongly opposed expanding Medicaid to cover health care for childless adults earning less than 75 percent of the poverty guideline.

11 May 2010

Drugs News and Research

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Gap between Hispanic and white asthma sufferers widen in the use daily medications

Daily dose of iron reduces breath-holding spells in children by 90%: Studies

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

PharmedOut to host conference to explore influence of pharmaceutical industry on medical education

Studies: Trauma centers would be strained by patient load in terrorist attack

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

Vetter signs preferred partnership agreement with Sentry BioPharma Services

R.I. overhauls Medicaid payments for elderly, disabled; Medicaid delays reported in Kansas

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences’ Luveniq NDA

Group worries about proposals to allow drug marketing on social media websites

Anti-inflammatory drugs help block kidney destruction that occurs with hypertension: Researchers

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Tianyin third-quarter revenue up 60%

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Bionovo reports net loss of $4.7M for first-quarter 2010

China Pharma first-quarter revenue up 16% to $15.1 million

Minn. negotiators seek compromise to expand Medicaid while a nursing home tax and cuts to a screening program grab headlines in other states

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News